We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NYXH:NASDAQNyxoah SA Analysis

Data as of 2026-08-24 - not real-time

$1.62

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Nyxoah SA is bearish at $1.62, with short-term averages lagging the long-term ones. Over a rolling month the price has lost 1.2%. With RSI at 53.8 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at $1.30 and resistance at $1.70.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 170.2% above today's level. Revenue is growing at 472.8%.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 57.2%, a beta of 2.18 and a maximum drawdown of 79.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.

Top Market Events

Nyxoah SA NYXH stock is up during Tuesday’s premarket session.Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27,...The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 3.35
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 3.35
  • Analyst targets imply +170.2% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +170.2% versus the current price
  • Negative return on equity of -122.7%
  • Revenue growth of +472.8%

Key Metrics & Analysis

Financial Health

Revenue Growth472.80%
P/E Ratio-1.7
ROE-122.68%
ROA-36.87%
Debt/Equity72.18
P/B Ratio1.7
Op. Cash Flow$-71855000
Free Cash Flow$-46059124
Industry P/E31.1

Technical Analysis

TrendBearish
RSI53.8
Support$1.30
Resistance$1.70
MA 20$1.52
MA 50$1.57
MA 200$3.35
MACDBullish
VolumeDecreasing
Fear & Greed Index93.13

Valuation

Target Price$4.38
Upside/Downside170.23%
GradeFair
TypeGrowth

Risk Assessment

Beta2.18
Volatility57.16%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.